Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Targacept to get $2M from AZ
November 2007
SHARING OPTIONS:

WINSTON-SALEM, N.C.—Targacept Inc., a clinical-stage biopharma developing a new class of drugs called NNR Therapeutics, has announced that AstraZeneca has secured an option for an exclusive license to Targacept's product candidate TC-5619 under terms of an existing collaboration agreement. As a result, AstraZeneca will make a $2 million payment to Targacept. Neuronal nicotinic receptors (NNRs) are a class of receptors found in the nervous system that play a critical role in modulating the release of neurotransmitters to regulate nervous system activity. The alpha7 NNR subtype has been shown in animal studies to be a key regulator of cognitive function. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.